Technical briefing on Biopharmaceutical Innovation: The Value of Legal Certainty
Date
16 April 2012
Time
13:15 to 14:40
Location
World Intellectual Property Organization, Room B
Attend
This event has now passed. To browse our upcoming events click here.
Biopharmaceutical R&D is an extremely challenging and complex process that remains crucial for the development of new medicines capable of bettering the lives of millions all over the world. Over the centuries, key medical discoveries have been possible thanks to the utilization of Genetic Resources and their connected Traditional Knowledge. In order to ensure benefit-sharing and the sustainability of the R&D process, a clear and unambiguous legal environment is of pivotal importance. This IFPMA Briefing is intended to improve understanding of this complex issue through the direct experience of the biopharmaceutical industry.
Program
Lunch
Welcome & Introduction
Biopharmaceutical Innovation:
the Complexity of the R&D Process
Dr. Markus Boehringer, Head of
External Innovation & Alliances CVM
Diseases, F. Hoffmann-La Roche Ltd.,
Basel
The Industry’s Perspective
Mr. Andrew Jenner, Director,
Innovation, Intellectual Property
and Trade, IFPMA, Geneva
Discussion and Q & A
Speakers
Dr. Markus Boerhinger received his PhD in chemistry from the ETH Zuerich,
Switzerland. After a postdoctoral stay at Boulder, Colorado, he joined Roche as a
medicinal chemist.
Since then he has been leading project teams and groups within Medicinal
Chemistry and Metabolic research. In addition, he was leading the Discovery
Technologies department of Roche Basel. In this role he was also responsible for
the global compound repository and the high throughput screening labs.
Currently Head of External Innovation & Alliances, CVM Diseases at F. HoffmannLa
Roche Ltd. Markus Boehringer is leading today a global network of
collaborations between Roche and various academic institutes.
Mr. Andrew Jenner is a Director of Innovation, Intellectual Property (IP) & Trade at
the International Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) based in Geneva, Switzerland. He is responsible for developing
pharmaceutical industry strategy on Intellectual Property policy and represents the
industry on IP and trade related issues within the UN and the World Trade
Organization.
From 2007 until 2009 he was a Senior Policy Advisor and Head of the IP Crime
Policy Group for the UK Intellectual Property Office (IPO), and from 2004 – 2007 he
was Head of Trade & Development at the IPO. He first joined the UK Government
in 1998 as a patent examiner having previously worked in the automotive industry
as a quality control advisor.
He remains a member of the Institute of Engineering and Technology having a
Bachelor degree in Engineering and a Master of Laws.